PhD Position: β-catenin Inhibition in Colorectal Cancer Models

This PhD position at the Princess Maxima Center in Utrecht focuses on evaluating novel β-catenin inhibitors for colorectal cancer treatment. The project aims to test the efficacy and selectivity of these inhibitors on cancerous and normal cells using advanced in vitro (cell/organoid cultures) and in vivo (mouse models) approaches. The research will also involve genomic and transcriptomic profiling to identify cancer subtypes responsive to β-catenin inhibition, contributing to patient stratification for personalized treatment strategies. The work is part of a broader MSCA Doctoral Network, integrating functional testing with clinical relevance through collaboration with medical partners.

• Test the efficacy and selectivity of novel β-catenin inhibitors on normal and cancerous cells using in vitro cultures (cell lines/organoids) and in vivo mouse models.
• Conduct genomic and transcriptomic profiling to identify cancer subtypes responsive to β-catenin inhibition.
• Develop and characterize in vitro cell lines, organoids, and epithelioid cultures from mouse and human epithelial tissues.
• Use lineage tracing, in vivo tumor models, and spatial imaging to evaluate compound delivery, efficacy, and selectivity.
• Collaborate with clinical partners to ensure access to patient material and translate findings into clinically relevant strategies.
• Perform a 3-month secondment at ULX for BRET assay of β-catenin interactions in human cancer cell models.
• Contribute to the overall research program by providing biological rationale for patient stratification and informing compound progression within the consortium.